HomeAI · summaries
Storia in 3 fonti
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monda
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC, MLTX, FRVO, and SMCI.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster”…
- ·
statnews.com
AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
- ·
benzinga.com
Crude Oil Falls Over 2%; Getty Images Shares Spike Higher - AbbVie (NYSE:ABBV), Apogee Therapeutics (NASD
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 points on Monday. The Dow traded up 0.28% to 51,709.06 while the NASDAQ fell 1.31%…
- ·
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monda
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM,…
- ·
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.